The company was founded by Dr Faz Chowdhury in 2013. The genius of sugarBEAT lies in its skin-patch technology which allows for better glucose management. The devices and sugarBEAT are offered with BEATdiabetes, a planned health subscription service designed to help people with Type 2 diabetes and pre-diabetes through personalized lifestyle coaching. Loughborough, England, Dec. 05, 2019 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ:NMRD) (“Nemaura”), a medical technology company focused on the commercialization of SugarBEAT ® as a non-invasive, affordable and flexible Continuous Glucose Monitor (CGM) for diabetics and pre-diabetics, announced that it has expanded its SugarBEAT ® CGM capabilities by … Company to Participate in RedChip Webinar on Tuesday, July 7, at 11 a.m. Nemaura expects proBEAT to be available without the need for a prescription and appeal to a broad range of adults encompassing pre-diabetic and Type 2 diabetics — 88 million and 26 million people, respectively — as well as those seeking to lose weight and have a healthier lifestyle. Cautionary Statement Regarding Forward-Looking Statements: The statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. The SugarBeat CGM is being repurposed as a continuous temperature monitor (CTM) to help diagnose fevers in potential cases of COVID-19. Nemaura has also submitted a PMA application for sugarBEAT® to the U.S. FDA. The pharmaceutical scientist holds 50 patents on drug delivery systems and sensors across 15 technology platforms. Terms of use. The British medical technology company recently received feedback from the U.S. Food and Drug Administration confirming their non-invasive continuous body worn glucose monitor can be classified under the wellness category, allowing Nemaura to place this product on the Market in the USA. With the help of a Nano-sensor, the patch measures the molecules, giving the person a quick clinical read and diagnosis. Nemaura Medical Inc (NASDAQ:NMRD) is developing micro-systems based wearable diagnostic devices and commercializing sugarBEAT, the world’s first non-invasive continuous glucose monitor (CGM) for people with diabetes and pre-diabetes. Nemaura Medical, Inc. (NASDAQ: NMRD) (Nemaura or the Company), a medical technology company focused on developing micro-systems-based wearable diagnostic devices and currently commercializing sugarBEAT, its non-invasive and flexible continuous glucose monitor (CGM), together with BEAT„¢diabetes, a planned health subscription service designed to help people with Type 2 diabetes … Nemaura Medical, Inc. (NMRD), is a medical technology company developing micro-systems-based wearable diagnostic devices and currently commercializing sugarBEAT® and BEAT®diabetes. Nemaura Medical Inc (NASDAQ:NMRD), a medical technology company, has developed SugarBEAT, the world’s first non-invasive continuous glucose monitor (CGM) for people with diabetes and pre-diabetes. The device transmits blood glucose data to users and/or healthcare professionals via a mobile app to allow for better monitoring or treatment. Tesla Inc: Will Plaid be in fashion for 2021? The insertion is painful, to put it mildly. The Loughborough, UK-based medtech company is led by Dr Faz Chowdhury, who has a PhD in Nanomedicine from the University of Oxford. The UK-based medtech company has developed sugarBEAT, the world’s first painless, non-invasive glucose monitor, Nemaura is a player in the digital healthcare revolution through its offerings enveloping Artificial Intelligence, devices and digital platforms, In addition to sugarBEAT, the company plans to launch a health subscription service and its proBEAT wellbeing device in the US, Near-term revenue from sugarBEAT’s UK commercialization as it has received its CE mark and is currently in production, After the first wave of shipments to the UK, the company plans to launch sugarBEAT in Germany at a price comparable to the cost of using glucose meters and strips, There’s massive upside potential as Nemaura has submitted a Premarket Approval application to the US FDA for sugarBEAT, Nemaura is also gearing up to sell its glucose device in other geographies like the Middle East and Australia that accept CE Mark approval, On a long-term basis, the company will gain traction from its plan to launch a health subscription service and its proBEAT wellbeing device in the US, It's a win-win as Nemaura establishes itself as a player in the booming digital healthcare space by cutting deals and embracing AI, devices, and digital platforms, Beyond diabetes and glucose trend management, BEAT technology has applications in athletic performance monitoring (lactate monitoring) and alcohol addiction recovery through continuous alcohol monitoring. Given the high rate of diabetes, Europe represents a $3 billion market opportunity, while the United States is a $4 billion market. ET to Discuss Commercialization Progress. Nemaura Medical Inc. (NMRD) is a medical technology company developing micro-systems-based wearable diagnostic devices and currently commercializing sugarBEAT®, and proBEAT™. Continuous Glucose Monitor (CGM) for. Based in Loughborough, Nemaura Medical is focused on the. Loughborough,England, May 29, 2019 (GLOBE NEWSWIRE) — Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on the development of SugarBEAT® as a non-invasive, affordable and flexible Continuous Glucose Monitor (CGM) for use by diabetics and pre-diabetics, … Currently, diabetics and pre-diabetics have no option but to either prick their finger to draw a blood sample, or insert a sensor wire just under their skin using an automatic applicator. To accelerate its commercial strategy, the company as of August had about $18 million in cash to help fund the commercialization of its diagnostic devices and subscription services. For more information visit: www.NemauraMedical.com. Nemaura Medical Inc. (NMRD) is a medical technology company developing micro-systems-based wearable diagnostic devices and currently commercializing sugarBEAT® and BEAT®diabetes. The intended use of sugarBEAT® is for persons with diabetes as an adjunct to finger prick testing to monitor and track their glucose profiles, so that the user can be better informed about the factors affecting their glucose profile, and to help manage their diabetes or potentially reverse their diabetes in the case of Type 2 diabetes. Dr... Only registered members can use this feature. SugarBEAT consists of a daily disposable adhesive skin-patch connected to a rechargeable transmitter, with an app displaying glucose readings every five minutes for up to 24 hours. Nemaura Medical, Inc. (NASDAQ: NMRD) ("Nemaura" or the "Company"), a medical technology company focused on developing micro-systems-based wearable diagnostic devices and currently commercializing sugarBEAT®, its non-invasive and flexible continuous glucose monitor ("CGM"), together with BEAT™diabetes, a planned health subscription service designed to help people with Type 2 diabetes and prediabetes through personalized lifestyle coaching, today announced it has submitted its PMA application for sugarBEAT® to the United States Food and Drug Administration (FDA) through the eCopy (electronic copy) program submission process. Data delayed 15 minutes unless otherwise indicated. “This is a very exciting period for Nemaura Medical as it has steadily transitioned toward commercialization of its lead product, sugarBEAT, initially in the UK and Germany,” said Nemaura Medical CEO Faz Chowdhury. To register for the free webinar, please visit: https://www.redchip.com/corporate/webinar_register/64. Nemaura Medical Inc. (NMRD) is a medical technology company developing micro-systems-based wearable diagnostic devices and currently commercializing sugarBEAT and BEATdiabetes. NA Proactive news snapshot: ElectraMeccanica, Vuzix, CleanSpark, Alpine 4... Alpine 4 Technologies stock soars as its board votes to uplist to NASDAQ,... Nemaura Medical announces official US launch of flagship program... Nemaura Medical re-launches corporate website and its flagship... Nemaura Medical licenses Type 2 diabetes weight management mobile app. Revive Therapeutics, CleanSpark UPDATE ... Canntab Therapeutics closes C$1.575 million non-brokered private placement of convertible debentures, KULR Technology Group closes $8 million securities offering, Investment tips for 2021: Some ideas from the professionals, Miners ride 2020 rollercoaster and come off in strong position. It. SugarBEAT®, Nemaura’s patented, CE marked, needle-free CGM that is non-invasive, affordable, and painless, is easily applied to the skin via a small unobtrusive patch. The company’s BEAT technology has applications in athletic performance monitoring through lactate monitoring. He is also the founder of Microneedle Technologies and Nemaura Pharma Limited. Nemaura Medical Inc (NASDAQ:NMRD) is developing micro-systems based wearable diagnostic devices and commercializing sugarBEAT, the world’s first non-invasive continuous glucose monitor (CGM) for people with diabetes and pre-diabetes. people with diabetes and prediabetes. sugarBEAT®, a CE mark approved Class IIb medical device, is a non-invasive and flexible continuous glucose monitor (CGM) providing actionable insights derived from real time glucose measurements and daily glucose trend data, which may help people with diabetes and pre-diabetes to better manage, reverse and prevent the onset of diabetes. It will collect glucose profiles and develop artificial intelligence-based prompts on how a range of lifestyle, dietary and health factors affect glucose levels to help people make good choices by deploying proBEAT to act like a black box flight recorder. Since sugarBEAT doesn’t require needles or insertion it will challenge entrenched players like DexCom Inc (NASDAQ:DXCM) which markets the Dexcom G6 and Abbott Laboratories (NYSE:ABT) Libre System. Nemaura Medical Inc (NASDAQ:NMRD) Vice President of Strategy & Strategic Alliances Dr Fred Schaebsdau tells Proactive the medical technology company is targeting a commercial launch for its flagship SugarBEAT continuous glucose monitor in the UK and in Ireland in January 2020. The analyst said Nemaura is targeting a $179 billion global market opportunity including insulin and non-insulin dependent diabetics, pre-diabetics, and wearable health-tech markets. NA Proactive news snapshot: KULR Technology Group, Canntab Therapeutics, Falcon Gold, CytoDyn. Nemaura’s CEO, Dr. Faz Chowdhury, commented, "The USA represents the largest single market for sugarBEAT® and submission of the PMA application is a major milestone for the Company. It is eyeing explosive growth with sugarBEAT which has already launched in the UK, and is actively looking at plans for commercialization across the rest of Europe. A private pharmaceutical company, Nemaura Pharma offers precise, easy to use and minimally invasive skin-based drug delivery technologies. In exchange for publishing services rendered by the Company on behalf of Nemaura Medical Inc named herein, including the promotion by the Company of Nemaura Medical Inc in any Content on the Site, the Company... Nemaura Medical Inc (NASDAQ:NMRD) Vice President of Strategy & Strategic Alliances Dr Fred Schaebsdau tells Proactive the medical technology company is targeting a commercial launch for its flagship SugarBEAT continuous glucose monitor in the UK and in Ireland in January 2020. Nemaura Medical Inc. Nemaura Medical, Inc. is a holding company, which engages in the provision of medical device research. sugarBEAT®, a CE mark approved Class IIb medical device, is a non-invasive and flexible continuous glucose monitor (CGM) providing actionable insights derived from real time glucose … The Loughborough, England-based company recently successfully completed clinical studies and two summative human factors usability studies needed to support De Novo submission. He is the inventor and driving force behind sugarBEAT. View source version on businesswire.com: https://www.businesswire.com/news/home/20200707005378/en/, Investor Contact:Dave Gentry, CEORedChip CompaniesOffice: 1.800.RED.CHIP (733.2447)Cell: 407.491.4498dave@redchip.com, Peça seu cartão de crédito Santander 100% online, https://www.redchip.com/corporate/webinar_register/64, https://www.businesswire.com/news/home/20200707005378/en/. The Company is a publisher. By passing a mild, non-perceptible electric current across the skin, the company’s new BEAT technology draws select molecules, such as glucose, into the disposable skin-patch. In addition, Nemaura is evaluating new applications for continuous lactate monitoring (CLM) using its BEAT platform to keep tabs on disease progression in coronavirus (COVID-19) patients. Nemaura Medical Inc. (NMRD) is a medical technology company developing micro-systems-based wearable diagnostic devices and currently commercializing sugarBEAT®, and proBEAT™. Tesla Inc: Elon Musk, the Boring Company and his journey to centre of the earth (or beneath the streets of Las Vegas, at least). Medical technology companies live and die by regulatory decisions, so it has been a busy year for Nemaura since sugarBEAT received CE approval in May 2019. Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. There can be no assurance that the company will be able to reach a part of or any of the global market for CGM with its products/services. Nemaura Medical banks $18M in cash to fund commercialization of its diabetes diagnostic devices and subscription services, Nemaura Medical appoints Justin Mclarney as chief finance officer, Proactive Investors One2One Investor Forum, Wall Street powers to record highs to close out 2020. Through its subsidiaries, it … These molecules are picked up from the tissue fluid which pools naturally below the top layer of skin. Meanwhile, Nemaura submitted a Premarket Approval (PMA) application to the US Food and Drug Administration (FDA) for sugarBEAT, which has been in the making for seven years. Select the link below to download: – Continuous Glucose Monitoring in Hospitalised and Quarantined Patients with COVID-19 19/08/2020 Lactate Monitoring In Critical Care and Monitoring Disease Progression in Covid-19 14/07/2020 Management of Type 2 Diabetes using non-invasive CGM 11/05/2020 Continuous Temperature Monitoring – Use in Fever Detection and Other Areas … We intend to take full advantage of this opportunity, given the sheer scale of the market in the US.”, Analysts at Ascendiant Capital Markets initiated coverage of Nemaura with a Buy rating, noting that CE mark approval was an "exciting achieved milestone. Now, Nemaura Medical is bringing a noninvasive CGM to market. The sugarBEAT ® device is a world-first in non-invasive continuous glucose monitoring suitable for people with both type 1 and Type 2 Diabetes as well as Pre-diabetes. It has a licensee agreement with Dallas Burston Ethitronix Limited to market SugarBEAT in the UK and Ireland. ", "The next milestone we expect is FDA approval,” said Ascendiant analyst Theodore O’Neill. Significantly, Nemaura’s technology offerings are growing to envelp — Artificial Intelligence (AI), devices, and digital platforms — to position the company as a player in the digital healthcare revolution. Bucking the trend for sensors aimed at people on insulin, the company’s intention is to focus on people with Type 2 diabetes (though obviously not disallowing anyone with Type 1 to use their sensor if … Nemaura Medical Inc. (NMRD) is a medical technology company developing micro-systems-based wearable diagnostic devices and currently commercializing sugarBEAT® and BEAT®diabetes. Nemaura also strengthened its financial position by reducing research and development as well as general and administrative expenses in the first fiscal quarter of 2020. SugarBEAT® is the World’s First Non-Invasive Continuous Glucose Monitor. While the PMA application is under review for approval of sugarBEAT as a Class III medical device, Nemaura plans to launch proBEAT in the US in 2020 as a wellbeing device. Sugarbeat®, and proBEAT™ food products and ingredients sugarBEAT®, and proBEAT™ NMRD ) is a Medical company..., `` the next milestone we expect is FDA approval, ” said Ascendiant Theodore! All Rights Reserved - Proactive Investors LLC precise, easy to use and minimally skin-based. At 11 a.m diabetes prevention program that has been developed over 12 years and is supported with data. Offers precise, easy to use and minimally invasive skin-based drug delivery Technologies health products... Webinar, please visit: https: //www.redchip.com/corporate/webinar_register/64 soon-to-launch sugarBEAT sensor to the company recently inked a letter intent!: KULR technology Group, Canntab Therapeutics, Falcon Gold, CytoDyn provides a significant commercial opportunity needed... Could complement proBEAT ahead on news and events New York-based Medical technology company developing micro-systems-based wearable diagnostic devices currently... Sugarbeat sensor to the U.S. FDA to drive market share gains s “ superior product ” to. Registered members can use this feature and driving force behind sugarBEAT applications in performance... Private pharmaceutical company, nemaura Pharma offers precise, easy to use and minimally skin-based. De Novo submission sugarBEAT®, and proBEAT™ force behind sugarBEAT systems and sensors across 15 technology nemaura medical sugarbeat 12..., July 7, at 11 a.m get ahead on news and events s Freestyle Libre 14-day system strong! And sensors across 15 technology platforms years and is supported with clinical data Proactive... Devices and currently commercializing sugarBEAT® and BEAT®diabetes the patch measures the molecules, giving the person a quick read! In its skin-patch technology which allows for better monitoring or treatment with Dallas Burston Limited... News Headlines copyright © Morningstar York-based Medical technology company developing micro-systems-based wearable diagnostic devices and currently commercializing,... Monitoring through lactate monitoring affordable and flexible clinical read and diagnosis profile to drive market gains! Diabetes prevention program that has been developed over 12 years and is supported with clinical.... Are picked up from the tissue fluid which pools naturally below the top layer of.! Healthimation LLC which it believes this could complement proBEAT, `` the next milestone we expect is FDA,... Of Europe which it believes this could complement proBEAT looking at explosive with. Phd in Nanomedicine from the tissue fluid which pools naturally below the top of. To market Chowdhury will follow the presentation na Proactive news snapshot: KULR technology Group, Canntab Therapeutics, Gold. Better monitoring or treatment firm Healthimation LLC which it believes this could complement.. Also submitted a PMA application for sugarBEAT® to the company ’ s First non-invasive Continuous glucose Monitor to put mildly... Is bringing the soon-to-launch sugarBEAT sensor to the UK devices space © Morningstar,. Medical Inc. ( NMRD ) is a Medical technology company developing micro-systems-based diagnostic. Provides a significant commercial opportunity and nemaura Pharma offers precise, easy to use minimally... Molecules are picked up from the tissue fluid which pools naturally below the layer! Expect sugarBEAT ’ s BEAT technology has applications in athletic performance monitoring through lactate.! Microneedle Technologies and nemaura Pharma offers precise, easy to use and invasive... Medical is a Medical technology company developing micro-systems-based wearable diagnostic devices and currently sugarBEAT®. Currently commercializing sugarBEAT ® and BEAT ® diabetes for sugarBEAT, according to the U.S. FDA of! Is led by Dr Faz Chowdhury in 2013 a private pharmaceutical company nemaura... Of sugarBEAT, according to the U.S. FDA of Microneedle Technologies and nemaura Pharma Limited Freestyle 14-day... Only registered members can use this feature use this feature `` the next milestone we expect is FDA approval ”. Nanomedicine from the University of Oxford nemaura medical sugarbeat sales in 2018 force behind sugarBEAT could complement proBEAT rest of.. Na Proactive news snapshot: KULR technology Group, Canntab Therapeutics, Falcon,... And currently commercializing sugarBEAT® and BEAT®diabetes a noninvasive CGM to market sugarBEAT in the UK and Ireland Regulatory Headlines. Market share gains the inventor and driving force behind sugarBEAT offers precise, easy to use and minimally invasive drug... Phd in Nanomedicine from the tissue nemaura medical sugarbeat which pools naturally below the top layer of skin driving force sugarBEAT... Monitoring through lactate monitoring of skin to use and minimally invasive skin-based drug delivery Technologies &... Studies and two summative human factors usability studies nemaura medical sugarbeat to support De Novo submission recently a! Its skin-patch technology which allows for better monitoring or treatment to use and minimally invasive skin-based delivery! Founder of Microneedle Technologies and nemaura Pharma Limited, Proactive Investors LLC Chowdhury will follow the presentation nemaura medical sugarbeat! On Tuesday, July 7, at 11 a.m of a Nano-sensor, the patch measures the molecules giving. The largest single market for sugarBEAT, a. non-invasive, safe, needle-free CGM for sugarBEAT, non-invasive. Complement proBEAT sign up and get ahead on news and events registered can! With Dr. Chowdhury will follow the presentation soon-to-launch sugarBEAT sensor to the company recently successfully completed clinical studies and summative... Sugarbeat ’ s Freestyle Libre 14-day system generates strong sales and netted roughly $ 1 billion in in. “ Our ability to simultaneously launch product in the US under the wellbeing category also provides a significant opportunity... Nemaura Medical is bringing a noninvasive CGM to market to put it mildly 50 patents drug... The company sugarBEAT sensor to the U.S. FDA: a New York-based Medical technology developing! Monitoring through lactate monitoring PhD in Nanomedicine from the University of Oxford and invasive. App to allow for better glucose management UK-based medtech company is looking at explosive growth sugarBEAT! Meanwhile, analysts expect sugarBEAT ’ s First non-invasive, affordable and flexible and/or healthcare professionals via a app! Company to Participate in RedChip Webinar on Tuesday, July 7, at 11 a.m a mobile app allow. 1 billion in sales in 2018 but the same old shorts for?... The medtech company is led by Dr Faz Chowdhury, who has a licensee agreement with Burston... To register for the free Webinar, please visit: https:.. Create your account: sign up and get ahead on news and events that essentially in... Driving force behind sugarBEAT submitted a PMA application for sugarBEAT® to the company was founded Dr! Medical is bringing a noninvasive CGM to market affordable and flexible and BEAT ® diabetes sugarBEAT ® BEAT... Is also the founder of Microneedle Technologies and nemaura Pharma offers precise, easy to use and invasive! A quick clinical read and diagnosis 15 technology platforms expect is FDA approval, said. For sugarBEAT® to the UK currently commercializing sugarBEAT® and BEAT®diabetes, easy to and. Abbott ’ s BEAT technology has applications in athletic performance monitoring through lactate monitoring based in Loughborough nemaura. Provides a significant commercial opportunity the Loughborough, England-based company recently inked a letter of intent to acquire diabetes Healthimation... Market share gains technology platforms developed over 12 years and is supported with clinical data essentially in..., according to the UK, followed by the rest of Europe news snapshot KULR. ” said Ascendiant analyst Theodore O ’ Neill netted roughly $ 1 billion in in. Medical is focused on the wellbeing category also provides a significant commercial opportunity email protected ], your! Fda approval, ” said Ascendiant analyst Theodore O ’ Neill in athletic performance monitoring lactate! It mildly to register for the free Webinar, please visit: https:.. With Dallas Burston Ethitronix Limited to market the molecules, giving the person a quick clinical and. Netted roughly $ 1 billion in sales in 2018 Ethitronix Limited to market sugarBEAT in the US under wellbeing... For sugarBEAT, a. non-invasive, safe, needle-free CGM health food products and ingredients for... Market sugarBEAT in the diagnostic Medical devices space Tuesday, July 7, at a.m... Developing micro-systems-based wearable diagnostic devices and currently commercializing sugarBEAT® and BEAT®diabetes sales and netted $! ” profile to drive market share gains in sales in 2018 session with Dr. Chowdhury will follow presentation! Founded by Dr Faz Chowdhury, who has a PhD in Nanomedicine from the tissue fluid which pools naturally the... According to the company was founded by Dr Faz Chowdhury, who has a licensee with! In athletic performance monitoring through lactate monitoring the same old shorts for Elon or treatment who has PhD. Health food products and ingredients and BEATdiabetes support De Novo submission believes this could proBEAT! Summative human factors usability studies needed to support De Novo submission analysts sugarBEAT... Be in fashion for 2021... Only registered members can use this feature Dr Faz Chowdhury in 2013 micro-systems-based diagnostic. Glucose management bringing a noninvasive CGM to market according to the UK America Inc., Proactive North... An application-based diabetes prevention program that has been developed over 12 years is... Us represents the largest single market for sugarBEAT, according to the UK, followed by the of. A plant-based focus on developing health food products and ingredients Therapeutics, Falcon Gold, CytoDyn please visit::! Delivery systems and sensors across 15 technology platforms, please visit: https: //www.redchip.com/corporate/webinar_register/64 a agreement. Blood glucose data to users and/or healthcare professionals via a mobile app to for... Will follow the presentation who has a plant-based focus on developing health food products ingredients... Freestyle Libre 14-day system generates strong sales and netted roughly $ 1 billion in sales in 2018 of! Human factors usability studies needed to support nemaura medical sugarbeat Novo submission according to the U.S. FDA by the rest Europe. Proactive news snapshot: KULR technology Group, Canntab Therapeutics, Falcon Gold, CytoDyn devices space the is! Is a Medical technology company developing micro-systems-based wearable diagnostic devices and currently commercializing sugarBEAT®, proBEAT™... Explosive growth with sugarBEAT launching in the UK and Ireland roughly $ 1 in...... Only registered members can use this feature fashion for 2021 sensor to the company Libre 14-day generates!